ClinicalTrials.gg
CompletedNCT01308619Updated Aug 1, 2022Results posted

Evaluation of Rosacea-related Inflammatory Biochemical Markers in Adult Skin When Treated With Oracea® vs Placebo

A Phase 4 interventional study of Doxycycline and Placebo in Rosacea, sponsored by Galderma R&D. Completed at 10 sites in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2022-08-01.

Sponsored by Galderma R&D (part of Galderma Group AG) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
170
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing doxycycline in Rosacea — none open to participants now, 1 under way, none of them phase 3. Doxycycline · Rosacea.

Enrollment
5th of 12
170 · median 150
Started
2011
with 1 other
Phase 4
6 of 12
none open now
Registered
5th of 12
by date
Lead sponsor
4 of 12
Galderma R&D

Among the 12 studies testing doxycycline in Rosacea, this one is the 5th largest by enrollment, is one of 2 that started in 2011, is one of 6 in phase 4, and was the 5th registered.

Rosacea

233 studies on the registry are indexed under Rosacea; 22 are open to participants now.

Browse Rosacea studies →

Open to participants now

None of the 12 studies testing doxycycline in Rosacea is open now. The open studies under Rosacea, anywhere →

Where they have run

About doxycycline

Doxycycline: first FDA approval 1967 (VIBRAMYCIN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 16 Rosacea studies recruiting now, 9 (56%) set no upper age limit and 6 (38%) stop at 75 or younger; 1 takes children under 18; 8 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies testing doxycycline in Rosacea as a file.
02

Study summary

The objective of this study is to determine the clinical effects of doxycycline 40 mg (30 mg immediate release and 10 mg delayed release beads) capsules (Oracea®) as compared to placebo in the skin of adults with papulopustular rosacea and to identify a correlation, if any, with rosacea-related inflammatory markers.

03

Conditions studied

  • Rosacea

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject is male or female aged 18 to 70 years inclusive
  • Subject with papulopustular rosacea (5 to 40 papules or pustules)

Exclusion criteria

Exclusion Criteria:

  • Subject has any other active dermatological condition on face that may interfere with the conduct of the study
  • Subject uses proton pump inhibitors for treatment of gastroesophageal reflux within 30 days prior to baseline visit or during the study
  • Subject uses spironolactone within 30 days prior to baseline visit or during the study
  • Subject requires chronic treatment (>14 days) with sulfa drugs, erythromycin, cephalosporins and quinolones within 30 days prior to baseline visit or during the study
  • Subject has used tetracycline antibiotics within 30 days prior to baseline visit or during the study
  • Subject has used penicillin antibiotics within 30 days prior to baseline visit or during the study
  • Subject uses topical or oral dapsone
  • Subject has had a change in hormonal therapy within 3 months of initiation of therapy or during the study
  • Subject has used systemic (e.g. , cyclosporine, imuran, biologics, mycophenolate mofetil) within 30 days prior to baseline visit. For subjects who have received treatment with biologics, treatment must have been discontinued within 90 days prior to baseline
  • Subject has used any systemic therapy directed at improving rosacea, including antibiotics, within 30 days prior to baseline visit
  • Subject has used systemic retinoids within 6 months of the baseline visit
  • Subject takes niacin at a dosage of 500 mg or more per day
  • Subject has used any topical rosacea therapy including topical antibiotics, topical retinoids, topical sodium sulfacetamide preparations, topical benzoyl peroxides, topical vasoconstricting agents (e.g., oxymetazoline) topical calcineurin inhibitors (e.g. tacrolimus, pimecrolimus) within 30 days prior to baseline visit
  • Subject has been treated with another drug or device within 30 days of baseline visit. For subjects who received experimental biologic treatment, treatment must have been discontinued within five half lives of the baseline visit.
  • Subject has a known allergy to any of the components of the study products, and/or a known to tetracyclines
  • Subject is using a concomitant drug (e.g., use of long term non-steroidal anti-inflammatory agents unless used only on a PRN basis less than 7 days per month)
  • Subject has used vasodilators or an adrenergic blocking agent within 6 weeks of baseline visit (except subjects on stable dose for greater than 3 months)
  • Subject has had laser or light therapy on the face within 3 months of the baseline visit
  • Subject with active ocular rosacea and/or blepharitis/meibomianitis requiring systemic treatment by an ophthalmologist
  • Subject with rhinophymatous rosacea
  • Subject with a history of noncompliance with a treatment regimen
  • Subject is at risk in terms of precautions, warnings, and (see package insert)
  • Subject has previously failed to have improvement of rosacea with appropriate use of systemic tetracycline family of antibiotics
  • Subjects with a recent history of alcohol and/or drug abuse
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
170 participants (actual)

Study arms

  • Active comparator
    Oracea®

    Doxycycline 40 mg (30 mg immediate release / 10 mg delayed release beads) Capsules

    Drug: Doxycycline

  • Active comparator
    placebo

    placebo

    Other: Placebo

Interventions

  • doxycycline 40 mg (30 mg immediate release / 10 mg delayed release beads) Capsules, oral, one capsule daily in the morning

    Also known as: Oracea®

  • OtherPlacebo

    Placebo, oral, one capsule daily in the morning

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Inflammatory Lesion Counts

    Mean change in inflammatory lesion counts from baseline to week 12

    Time frame: baseline to week 12

Secondary outcomes

  1. Change From Baseline in Biochemical Markers of Rosacea From Tape Stripping and/or Skin Biopsy From Baseline to Week 12

    Mean change from baseline to week 12 in biochemical markers of rosacea and expression in skin samples. A biological marker is a substance used as an indicator of a biological state such as rosacea. Biochemical markers are serine protease activity and expression, metalloprotease activity and expression, and production of leucine leucine-37 \[LL-37\] peptide.

    Time frame: baseline to week 12

  2. Investigator's Global Assessment (IGA) Scores at Week 12

    Number of participants in each category of the Investigator's Global Assessment (IGA) scores at week 12. Investigator's Global Assessment evaluates papules and pustules of rosacea on a scale from 0 - 4 (0 = Clear, 1 = Near Clear, 2 = Mild, 3 = Moderate and 4 = Severe) with 0 being best and 4 being worst.

    Time frame: Week 12

  3. Change From Baseline in Clinician's Erythema Assessment (CEA) Scores

    Mean change in Clinician's Erythema Assessment (CEA) from baseline to week 12. Clinician's Erythema Assessment evaluates erythema on a scale from 0 - 4 (0 = None, 1 = Mild, 2 = Moderate, 3 = Significant and 4 = Severe) with 0 being best and 4 being worst.

    Time frame: baseline to week 12

07

Results

Posted Aug 5, 2014

Participant flow

First subject enrolled 9 May 2011, last subject last visit 2 July 2012

Participant flow — Overall Study
MilestoneOracea®Placebo Capsules
Started8486
Completed7783
Not completed73

Outcome measures

PrimaryChange From Baseline in Inflammatory Lesion Counts

Mean change in inflammatory lesion counts from baseline to week 12

Time frame:
baseline to week 12
Reported as:
Mean · inflammatory lesions
Change From Baseline in Inflammatory Lesion Counts
inflammatory lesionsOracea®Placebo
Change From Baseline in Inflammatory Lesion Counts-4.3 ± 7.9-3.2 ± 8.6
SecondaryChange From Baseline in Biochemical Markers of Rosacea From Tape Stripping and/or Skin Biopsy From Baseline to Week 12

Mean change from baseline to week 12 in biochemical markers of rosacea and expression in skin samples. A biological marker is a substance used as an indicator of a biological state such as rosacea. Biochemical markers are serine protease activity and expression, metalloprotease activity and expression, and production of leucine leucine-37 \[LL-37\] peptide.

Time frame:
baseline to week 12
Reported as:
Mean · micr grams protein
Change From Baseline in Biochemical Markers of Rosacea From Tape Stripping and/or Skin Biopsy From Baseline to Week 12
micr grams proteinTreatment SuccessTreatment Failure
Cathelicidin-0.0931 ± 0.5491-0.0379 ± 0.1545
KLK5-0.0034 ± 0.0110-0.0049 ± 0.0146
MMP9-0.0017 ± 0.0100-0.0021 ± 0.0233
Total Protease-22351.6 ± 102888.2-22540.9 ± 66146.2
SecondaryInvestigator's Global Assessment (IGA) Scores at Week 12

Number of participants in each category of the Investigator's Global Assessment (IGA) scores at week 12. Investigator's Global Assessment evaluates papules and pustules of rosacea on a scale from 0 - 4 (0 = Clear, 1 = Near Clear, 2 = Mild, 3 = Moderate and 4 = Severe) with 0 being best and 4 being worst.

Time frame:
Week 12
Reported as:
Number · participants
Investigator's Global Assessment (IGA) Scores at Week 12
participantsOracea®Placebo
Clear82
Near Clear2318
Mild3531
Moderate1220
Severe615
SecondaryChange From Baseline in Clinician's Erythema Assessment (CEA) Scores

Mean change in Clinician's Erythema Assessment (CEA) from baseline to week 12. Clinician's Erythema Assessment evaluates erythema on a scale from 0 - 4 (0 = None, 1 = Mild, 2 = Moderate, 3 = Significant and 4 = Severe) with 0 being best and 4 being worst.

Time frame:
baseline to week 12
Reported as:
Mean · units on a scale
Change From Baseline in Clinician's Erythema Assessment (CEA) Scores
units on a scaleOracea®Placebo
Change From Baseline in Clinician's Erythema Assessment (CEA) Scores-1.0 ± 2.9-0.8 ± 3.1

Adverse events

Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Oracea®—2/84 (2.4%)8/84 (9.5%)
Placebo—0/86 (0%)6/86 (7%)
Most frequent serious events
Most frequent serious events
EventOracea®Placebo
Chest painCardiac disorders1/840/86
Spontaneous abortionPregnancy, puerperium and perinatal conditions1/840/86
Most frequent other events
Most frequent other events
EventOracea®Placebo
nauseaGastrointestinal disorders3/841/86
sinusitisInfections and infestations3/842/86
upper respiratory infectionInfections and infestations2/843/86

Baseline characteristics

Age, Continuous
Age, Continuous(years)Oracea®PlaceboTotal
Mean49.6 ± 11.448.7 ± 10.849.1 ± 11.1
Sex: Female, Male
Sex: Female, Male(Participants)Oracea®PlaceboTotal
Female6160121
Male232649
Region of Enrollment
Region of Enrollment(participants)Oracea®PlaceboTotal
United States8486170
08

Study locations

10 sites
  • Burke Pharmaceutical Research
    Hot Springs, Arkansas 71913, United States
  • Therapeutics Clinical Research
    San Diego, California 92123, United States
  • Hudson Dermatology
    Evansville, Indiana 47714, United States
  • The Indiana Clinical Trials Center
    Plainfield, Indiana 46168, United States
  • Michigan Center for Research Corp
    Clinton Township, Michigan 48038, United States
  • Skin Search of Rochester, Inc
    Rochester, New York 14623, United States
  • Oregon Medical Research Center, PC
    Portland, Oregon 97223, United States
  • Derm Research
    Austin, Texas 78759, United States
  • J & S Studies, Inc.
    College Station, Texas 77845, United States
  • Suzanne Bruce and Associates, PA
    Houston, Texas 77056, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2011, a primary completion of Aug 2012 and a completion of Aug 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2014, 2 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 2, 2011
First posted
Mar 4, 2011
Start
Apr 2011
Primary completionActual
Aug 2012
CompletionActual
Aug 2012
Results first posted
Aug 5, 2014
Last update
Aug 1, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 1, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01308619
Lead sponsor
Galderma R&D
Responsible party
Sponsor
First posted
Mar 4, 2011
Start date
Apr 2011
Primary completion
Aug 2012
Completion
Aug 2012
Results posted
Aug 5, 2014
Last update
Aug 1, 2022

Study contacts

Ronald W Gottschalk, MD
study director · Galderma R&D

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Doxycycline

Start the discussion